Anavex Life Sciences Corp (AVXL)

[polarbear77]

Agreed whippinsaw re MS, when will we finally be provided additional information regarding this Multiple Sclerosis/Anavex/Biogen mystery?

The novel was just getting good and someone yanked the book away.

Fortunately we are not limited here to just one indication and just one pending new trial to focus on and belabor: http://www.anavex.com/pipeline/

Again though regarding MS, why was:

• MS newly discussed in this year’s 10-k? (and not in 2016)

• MS mentioned in the p/r Monday morning?

• Dr M reminding us about the positive & encouraging MS data from WSU testing during the Monday conf call?

• Dr M stating that they were still moving forward with the MS indication and that updates would be available in 2018 when they have “better clarity”?

• the MS indication included in the September 2017 CNS Partner Summit abstract?

• despite having an independent 3rd party highly respected lab’s (WSU/Dr Lisak) published positive Multiple Sclerosis preclinical study (in October), the progress bar & the MS indication recently removed from the company’s pipeline chart?

• one of Dr Lisak’s conclusions in this preclinical study that “Data presented indicates that ANAVEX ® 2-73 may promote remyelination in multiple sclerosis disease.” [Talon has pointed out several times the significance & importance to Biogen of remyelination for Multiple Sclerosis research.]

• (as talon also found) Biogen’s online video removed showing their MS lab/scientists discussing the focus/importance of remyelination in their MS research efforts? Why would they pull that video down (not long after it had been linked/discussed here on ihub and around the approximate 1 year anniversary of the Anavex MTA with Biogen? Seems odd, but likely just anecdotal.

Forgive the speculation & conjecture, but does a2-73 seem to “work” for MS or not?

WSU researchers (one of the top MS research labs) haven’t stopped their work; and they continue to publish and present their results & findings in a seemingly positive light and with efficacious language, right? Would they continue to spend their valuable time/resources on a non-encouraging endeavor (it’s been 2 or 3 years of research by now)?

If it doesn’t seem to “work” then why the first 4 points above from our CEO last week?

Is it as simple as: there’s still an ongoing MTA (per I/R person) and therefore a non disclosure agreement and we all just have to sit & wait until the book is returned to read the ending?

Lastly:

NOTICE that WSU’s Dr Lisak’s conclusion back in Feb 2016 (see below) simply concluded that a2-73 had the “potential to provide protection of OL in MS.”

WHEREAS his October 2017 conclusion ADDED “Data presented indicates that ANAVEX ® 2-73 may promote remyelination in multiple sclerosis disease.” And NOW states: “Further, data also demonstrates that ANAVEX ® 2-73 provides protection for oligodendrocytes (“OL’s”) and oligodendrocyte precursor cells (“OPC’s”), as well as central nervous system neurons in addition to helping repair by increasing OPC proliferation and maturation in tissue culture.”

In light of the above, would anyone really be surprised to learn that the Company (or a partner) moves Multiple Sclerosis forward in a clinical trial? Don’t MS sufferers deserve same?

What’s the goal of the MS Society? Haven’t they the funds to promote and encourage new treatment options/trials??

From Monday’s 10-k:
“Additionally, in October 2017 we presented additional data from a preclinical study on ANAVEX ® 2-73 related to multiple sclerosis. Data presented indicates that ANAVEX ® 2-73 may promote remyelination in multiple sclerosis disease. Further, data also demonstrates that ANAVEX ® 2-73 provides protection for oligodendrocytes (“OL’s”) and oligodendrocyte precursor cells (“OPC’s”), as well as central nervous system neurons in addition to helping repair by increasing OPC proliferation and maturation in tissue culture.”

From 2/17/16 Dr Lisak’s initial presentation on a2-73 / MS findings:
“Conclusion:
ANAVEX2-73, which like DM is a S-1R and NMDAR antagonist but differs in other activities, protects OL from cytotoxic mechanisms involved in pathogenesis of MS lesions. Studies to determine the relative roles of S-1R agonism, NMDAR antagonism and muscarinic activities are objectives for future studies. ANAVEX2-73 and DM are small molecules that enter the central nervous system and thus have potential to provide protection of OL in MS.”

https://actrims.confex.com/actrims/2016/meetingapp.cgi/Paper/1218

http://www.anavex.com/anavex-2-73-preclinical-data-in-new-indication-to-be-presented-at-actrims-2016/